The major areas of research interest is to build a comprehensive program of research on the serology of HPV natural infection and HPV vaccination. These studies utilize the biobank of specimens from the various studies on HPV in DCEG such as the Costa Rica HPV16/18 Vaccine trial. We will examine the immunological determinants of protection recently reported for the HPV-16/18 vaccine against infection with other, phylogenetically related HPV types. Since protection against heterologous HPV types is partial, vaccine failures for these HPV types are expected in the early years following vaccination. We will also perform a nested case-control study within CVT that will evaluate key immunological markers among vaccinated women who develop infections with the types for which partial protection has been observed (failures), and will compare them to those observed among a group of controls who did not develop these infections after vaccination (successes). This effort is expected to be a multiyear project that will require initial validation and evaluation of novel immunological markers that can subsequently be applied in the nested case-control study.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIACP010216-04
Application #
8763658
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2013
Total Cost
$931,625
Indirect Cost
Name
Division of Cancer Epidemiology and Genetics
Department
Type
DUNS #
City
State
Country
Zip Code
Robbins, Hilary A; Li, Yan; Porras, Carolina et al. (2014) Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis 14:120
Safaeian, Mahboobeh; Rodriguez, Ana Cecilia (2014) Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol 180:1076-81
Safaeian, Mahboobeh; Sherman, Mark E (2013) From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination. J Natl Cancer Inst 105:1524-6
Safaeian, Mahboobeh; Ghosh, Arpita; Porras, Carolina et al. (2012) Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 21:1547-54
Coseo, Sarah E; Porras, Carolina; Dodd, Lori E et al. (2011) Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure. Sex Transm Dis 38:976-82
Kemp, Troy J; Hildesheim, Allan; Safaeian, Mahboobeh et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29:2011-4
Baker, Rosalyn; Dauner, Joseph G; Rodriguez, Ana Cecilia et al. (2011) Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine 53:282-5
Safaeian, Mahboobeh; Quint, Koen; Schiffman, Mark et al. (2010) Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst 102:1794-804
Safaeian, Mahboobeh; van Doorslaer, Koenraad; Schiffman, Mark et al. (2010) Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. Arch Virol 155:367-70
Shebl, Fatma M; Pinto, Ligia A; García-Piñeres, Alfonso et al. (2010) Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev 19:978-81